Literature DB >> 25573650

Erratum to: Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies.

Chris Twelves¹, Javier Cortes, Linda Vahdat, Martin Olivo, Yi He, Peter A Kaufman, Ahmad Awada.

Abstract

Entities: Disease Species

Year: 2015 PMID： 25573650 PMCID： PMC4643566 DOI： 10.1007/s10549-014-3245-7

Source DB: PubMed Journal: Breast Cancer Res Treat ISSN： 0167-6806 Impact factor: 4.872

× No keyword cloud information.

Erratum to: Breast Cancer Res Treat (2014) 148:553–561 DOI 10.1007/s10549-014-3144-y

Unfortunately, in the original publication of the article, the number of patients in the eribulin group for the overall population in Fig. 2 was erroneously published as n = 1,602. The correct value should read as n = 1,062.

1 in total

1. Use of Tumor-infiltrating lymphocytes (TILs) to predict the treatment response to eribulin chemotherapy in breast cancer.

Authors: Shinichiro Kashiwagi; Yuka Asano; Wataru Goto; Koji Takada; Katsuyuki Takahashi; Satoru Noda; Tsutomu Takashima; Naoyoshi Onoda; Shuhei Tomita; Masahiko Ohsawa; Kosei Hirakawa; Masaichi Ohira
Journal: PLoS One Date: 2017-02-06 Impact factor: 3.240

1 in total